A-3 Price List_Langlara-Insulins-Basal.xlsx
XLSX spreadsheet 45 KB Posted
- Solicitation number
- HT9402-26-Q-9404
- Issued by
-
Defense Health Agency
About this file
This is a pricing template for the Department of War (DoW) Pharmacy Uniform Formulary Blanket Purchase Agreement (BPA) and Uniform Formulary Additional Discount Program (ADP) for basal insulin products being evaluated for the November 4-5, 2026 P&T Committee meeting. The file is a quote submission template intended for insulin manufacturers to provide pricing for newly approved drugs and existing agents under consideration for formulary placement.
The template includes three pricing submission sections: (1) BPA pricing for Military Treatment Facility and Mail Order venues with both Uniform Formulary After Step Therapy and Non-Formulary After Step Therapy scenarios requiring price per NDC package size and price per unit; (2) ADP pricing using Federal Ceiling Price (FCP) methodology with Non-FAMP pricing, additional refund percentages, and calculated retail refunds for Tier 2 and Tier 3 After Step Therapy scenarios; and (3) ADP pricing using Wholesale Acquisition Cost (WAC) discount methodology for retail refund calculations. The quote deadline is October 26, 2026. Manufacturers must submit fully executed signature pages, Quote Review Checklist, and complete pricing for all applicable NDC codes across the ten newly approved drug appendices included in the template. The pricing per unit must remain consistent across all available package sizes (30s, 100s, 1000s) within each dispensing venue, and agents with pens and vials may be considered as a single product if pricing per unit is similar. Prior authorization and step therapy requirements may apply to formulary placement decisions.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| A-3 Price List_Armlupeg-White Blood Cell Stim-Pegfilgrastims.xlsx | XLSX spreadsheet | |
| A-3 Price List_Bixlenvo-Antiretrovirals-Combinations.xlsx | XLSX spreadsheet | |
| A-3 Price List_Adquey-Atopic-Topical Agents.xlsx | XLSX spreadsheet | |
| A-3 Price List_Clotic-Antifungals-NA.xlsx | XLSX spreadsheet | |
| A-3 Price List_Etcamah-Breast Canc Agt-Estrogen Recptr Antag.xlsx | XLSX spreadsheet | |
| A-3 Price List - Nuzolvence -Antibiotics - NA.xlsx | XLSX spreadsheet | |
| A-3 Price List - Rezenopy - Alcohol Deterrents-Narcotic Antag.xlsx | XLSX spreadsheet | |
| FAR 52-225-6-Certificate.pdf | ||
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| A-3 RFQ HT9402-26-Q-9404 NAD.pdf | ||
| A-3 Price List - Beqalzi - Onc Agents - Non-BTKI CLL-SLP.xlsx | XLSX spreadsheet | |
| A-3 Price List - Mimrylo - Hematological Agents - NA.xlsx | XLSX spreadsheet | |
| A-3 Price List_Rasonque-Oncological Agents-RAS Inhibitors.xlsx | XLSX spreadsheet | |
| A-3 Price List_Lisraya - TIBs - NA.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf |
Show all 15
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the November 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 |
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend for Completely Excluded from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service.
Note: Some manufacturers have both an autoinjector/pen and a vial. The Committee may consider pens and vials as one product in determining the formulary placement if the pricing is similar per unit. Agents with RFQ not submitted or selected may be designated non-step preferred.
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #2 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 243INBAG1UFAS1M | Uniform Formulary | |||
| After Step Therapy | 1 or more | NO QUOTE | |||
| 243INBAG1NFAS1M | Non-Formulary | ||||
| After Step Therapy | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (non-FAMP Discount)
| UF ADP Appendix for the November 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 |
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend for Completely Excluded from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service.
Note: Some manufacturers have both an autoinjector/pen and a vial. The Committee may consider pens and vials as one product in determining the formulary placement if the pricing is similar per unit. Agents with RFQ not submitted or selected may be designated non-step preferred.
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | |||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (WAC Discount)
| UF ADP Appendix for the November 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 |
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend for Completely Excluded from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service.
Note: Some manufacturers have both an autoinjector/pen and a vial. The Committee may consider pens and vials as one product in determining the formulary placement if the pricing is similar per unit. Agents with RFQ not submitted or selected may be designated non-step preferred.
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DoW Uniform Formulary Class: | INSULINS | P&T Committee Meeting: | November 4-5, 2026 | ||
| DoW Uniform Formulary Subclass: | BASAL | Quotes due: | October 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 243INBAG1T2AS1M | Tier 2 | |||
| After Step Therapy | 1 or more | ||||
| 243INBAG1T3AS1M | Tier 3 | ||||
| After Step Therapy | 1 or more | ||||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
File details come from the government source that posted it. Updated .